LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Начало・Списък с акции・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Затворен

СекторЗдравеопазване

9.93 -0.8

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.86

Максимум

10.01

Ключови измерители
By Trading Economics
Приходи	42M 17M
Продажби	14M 169M
EPS	0.17
Марж на печалбата	10.237
Служители	499
EBITDA	54M 48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+58.48% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	706M 3.1B
Предишно отваряне	10.73
Предишно затваряне	9.93

Настроения в новините

By Acuity

41%

59%

135 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.925 / 7.38 Подкрепа & съпротива

Amicus Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.11.2025 г., 15:29 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 19:59 ч. UTC

Пазарно говорене

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28.11.2025 г., 19:47 ч. UTC

Пазарно говорене

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 18:16 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

28.11.2025 г., 18:08 ч. UTC

Пазарно говорене

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28.11.2025 г., 17:48 ч. UTC

Пазарно говорене

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

28.11.2025 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28.11.2025 г., 15:51 ч. UTC

Пазарно говорене

Canada Household Spending Edges Lower -- Market Talk

28.11.2025 г., 15:33 ч. UTC

Пазарно говорене

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28.11.2025 г., 15:21 ч. UTC

Пазарно говорене

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28.11.2025 г., 15:13 ч. UTC

Пазарно говорене

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

28.11.2025 г., 15:11 ч. UTC

Пазарно говорене

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28.11.2025 г., 14:51 ч. UTC

Пазарно говорене

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28.11.2025 г., 14:41 ч. UTC

Пазарно говорене

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28.11.2025 г., 14:37 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 14:33 ч. UTC

Пазарно говорене

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28.11.2025 г., 14:20 ч. UTC

Пазарно говорене

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28.11.2025 г., 14:10 ч. UTC

Пазарно говорене

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.11.2025 г., 13:39 ч. UTC

Пазарно говорене

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28.11.2025 г., 13:36 ч. UTC

Пазарно говорене

Canada's Economy Expands More Than Expected -- Market Talk

28.11.2025 г., 13:29 ч. UTC

Пазарно говорене

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28.11.2025 г., 13:27 ч. UTC

Пазарно говорене

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28.11.2025 г., 13:19 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Amicus Therapeutics Inc Прогноза

Ценова цел

By TipRanks

58.48% нагоре

12-месечна прогноза

Среден 15.88 USD 58.48%

Висок 21 USD

Нисък 11 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Amicus Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Amicus Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.925 / 7.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

135 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.